Osteoclasts are responsible for bone resorption, and thereby play an essential role in maintaining bone volume and homeostasis ([@bib13]). Dysregulation of osteoclast differentiation or function disrupts maintenance of bone homeostasis, which in turn leads to pathogenic conditions such as osteoporosis, rheumatoid arthritis, lytic bone metastases, or Paget's bone disease ([@bib33]). Thus, osteoclasts could potentially be targeted therapeutically to treat skeletal disorders. Osteoclasts originate from BM--derived monocyte/macrophage precursor cells of hematopoietic origin and are differentiated by signaling through the receptor activator of NF-κB ligand (RANKL; [@bib18]). RANKL induces osteoclast differentiation by activating the nuclear factor of activated T cells 1 (NFATc1), a transcription factor required for osteoclastogenesis ([@bib39]; [@bib16]; [@bib34]; [@bib38]). Activated NFATc1 induces expression of "osteoclastic" molecules essential for osteoclast differentiation and function, such as DC-specific transmembrane protein (DC-STAMP) to facilitate cell--cell fusion, cathepsin K (Ctsk) to promote bone matrix proteolysis, and NFATc1 to drive differentiation ([@bib42]; [@bib22]). Thus, signaling pathways mediated by positive regulators of NFATc1 in osteoclastogenesis have been intensively studied, whereas factors negatively modulating osteoclastogenesis are largely unknown.

B lymphocyte--induced maturation protein 1 (Blimp1) has been investigated in numerous cell types ([@bib11]) and is reportedly essential for specification and maintenance of primordial germ cells (PGCs) through silencing of somatic programs ([@bib30]). B cell lymphoma 6 (Bcl6) was originally identified as a protooncogene because its chromosomal translocation and constitutive expression promotes lymphomagenesis ([@bib32]). *Bcl6^−/−^* mice show impaired germinal center formation ([@bib7]). The roles of Blimp1 and Bcl6 have also been investigated in B cell and plasma cell development ([@bib40]; [@bib7]), as well as in T cells ([@bib5]; [@bib20]; [@bib8]; [@bib12]; [@bib23]; [@bib4]). However, the roles of Blimp1 and Bcl6, both of which are transcriptional repressors, have not previously been characterized in osteoclastogenesis or skeletal disorders, although mutations in Bcl6-associated molecules are reportedly seen in skeletal pathologies such as malformation of fingers and clavicles ([@bib28]). Recently, it was reported that inhibiting NFATc1 using the NFATc1 inhibitor FK506 actually resulted in reduced bone mass caused by inhibition of bone formation that was more potent than inhibition of osteoclastogenesis ([@bib17]). Therefore, additional regulators of osteoclast differentiation have been sought as factors that could potentially increase bone mass.

In this study, we identify two transcriptional repressors controlling osteoclastogenesis, Bcl6 and Blimp1. We show that Bcl6 negatively regulates expression of osteoclastic genes, i.e., *NFATc1*, *DC-STAMP*, and *Ctsk*, which are all NFATc1 targets. We found that Bcl6 is recruited to promoters of these genes, and that Bcl6 inhibits osteoclastogenesis. We also report that Blimp1 binds to the *Bcl6* promoter, likely suppressing its expression. Bcl6-deficient mice exhibited decreased bone mass with increased osteoclastogenesis, whereas osteoclast-specific Blimp1 conditional KO (cKO) mice showed impaired osteoclast differentiation and increased bone mass, likely resulting from Bcl6 dysregulation. Overall, our data demonstrate that an axis of transcriptional repressors is crucial to regulate osteoclastogenesis and bone homeostasis.

RESULTS
=======

Bcl6 is a negative regulator of osteoclastogenesis
--------------------------------------------------

RANKL stimulates osteoclastogenesis by activating NFATc1 ([@bib39]; [@bib16]; [@bib34]; [@bib38]). To identify genes potentially suppressed after RANKL stimulation of osteoclast precursor cells (BM macrophages \[BMMs\]), we undertook comparative microarray screens of BMMs treated with or without RANKL and found that expression of the transcriptional repressor *Bcl6* was down-regulated by RANKL ([Fig. 1 A](#fig1){ref-type="fig"}). *Bcl6* down-regulation by RANKL was confirmed by real-time RT-PCR, immunofluorescence, and immunoblot analysis ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20091957/DC1) and [Fig. 1 B](#fig1){ref-type="fig"}). Immunofluorescence analysis showed that Bcl6 was detected in the nuclei of M-CSF--dependent macrophages, but not in nuclei of multinuclear osteoclasts induced by RANKL ([Fig. 1 B](#fig1){ref-type="fig"}). Interestingly, chromatin immunoprecipitation (ChIP) assays showed that, in the absence of RANKL, Bcl6 was recruited to the *NFATc1* P1 promoter, a region critical for regulating *NFATc1* expression in osteoclasts, and was dismissed from the promoter after RANKL treatment. In contrast, NFATc1, an essential positive regulator of osteoclastogenesis, was absent from the *NFATc1* P1 promoter in the absence of RANKL, but recruited after RANKL stimulation ([Fig. 1 C](#fig1){ref-type="fig"}). These results suggest a potential role of Bcl6 in inhibiting osteoclastogenesis. Bcl6 overexpression also potently inhibited osteoclast differentiation in vitro ([Fig. 1 D](#fig1){ref-type="fig"}), suggesting that Bcl6 negatively regulates osteoclast differentiation and that its down-regulation after RANKL stimulation is critical to induce osteoclastogenesis.

![**Bcl6 is suppressed during osteoclastogenesis and inhibits osteoclast formation.** (A) *Bcl6* expression was examined by comparative microarray analysis between osteoclast precursors (M-CSF) and osteoclasts (M-CSF + RANKL) cultured for 6 d. (B) BMMs were cultured with or without RANKL for 8 d and subjected to immunofluorescence staining (left) and immunoblot (right) for Bcl6. Nuclei were visualized by DAPI. Bar, 25 µm. (C) Recruitment of NFATc1 and Bcl6 to the *NFATc1* P1 distal promoter was detected by ChIP assay. RAW264.7 cells were stimulated with or without RANKL for 48 h and subjected to ChIP analysis. (D) RAW264.7 cells transduced with Bcl6-overexpressing (Bcl6) or mock (control) retrovirus were cultured in the presence (RANKL) or absence (control) of RANKL for 5 d and stained with TRAP. Left, TRAP staining. (right) Numbers are means ± SD of multinuclear TRAP-positive cells in control or Bcl6-overexpressing RAW264.7 cells cultured with RANKL (\*\*, P \< 0.001; *n* = 6). Representative data of three independent experiments are shown (B--D).](JEM_20091957_RGB_Fig1){#fig1}

Bcl6 deficiency facilitates osteoclast formation
------------------------------------------------

To characterize the physiological roles of Bcl6 in osteoclastogenesis, we analyzed Bcl6-deficient (*Bcl6^−/−^*) mice. *Bcl6^−/−^* mice exhibited lower bone mass as detected by microradiographical and dual-energy x-ray absorptiometry analysis compared with heterozygous littermates (*Bcl6^+/−^*; [Fig. 2, A and B](#fig2){ref-type="fig"}). Consistently, histomorphometric analysis of *Bcl6^−/−^* mice demonstrated increased osteoclastogenesis and large osteoclast formation in *Bcl6^−/−^* mice. *Bcl6^−/−^* mice also showed elevated levels of serum C-terminal telopeptides of type I collagen (CTx) and decreased bone parameters ([Fig. 2, C and D](#fig2){ref-type="fig"}, and [Fig. S2](http://www.jem.org/cgi/content/full/jem.20091957/DC1)). In vitro, osteoclast progenitor cells isolated from Bcl6-deficient mice and treated with RANKL differentiated more rapidly into multinuclear tartrate-resistant acid phosphatase (TRAP)--positive cells than did those from control mice ([Fig. 2 E](#fig2){ref-type="fig"} and not depicted). Lower concentrations of RANKL not sufficient to differentiate control cells induced osteoclast differentiation of Bcl6-deficient cells ([Fig. 2 E](#fig2){ref-type="fig"}). Furthermore, increased bone resorbing activity was evident in Bcl6-deficient osteoclasts ([Fig. 2 F](#fig2){ref-type="fig"}), suggesting loss of a negative regulator of osteoclast function and differentiation. Deletion of Bcl6 in osteoclast precursor cells did not alter cell proliferation or induce apoptosis ([Fig. S3](http://www.jem.org/cgi/content/full/jem.20091957/DC1)). Thus, Bcl6 functions to regulate osteoclast differentiation and bone homeostasis, and its down-regulation by RANKL is required for osteoclast formation.

![**Increased osteoclast formation resulting from Bcl6 deficiency.** (A) Micro focus CT analysis of femurs of *Bcl6^+/−^* (left) and *Bcl6^−/−^* (right) mice. (B) Bone mineral density (BMD) of equal longitudinal division of femurs of *Bcl6^+/−^* (open circles) and *Bcl6^−/−^* (closed circles) mice. Data are mean BMD (mg/cm^2^) ± SD (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; *n* = 3). (C) TRAP staining of tibial sections of *Bcl6^+/−^* (top) and *Bcl6^−/−^* (bottom) mice, and osteoclast surface as a percentage of bone surface (OcS/BS). Data are means ± SD (\*\*, P \< 0.001; *n* = 5). (D) Serum levels of C-terminal teropeptides of type I collagen (CTx) were analyzed in *Bcl6^+/−^* (white bar) and *Bcl6^−/−^* (shaded bar) mice. Data are means ± SD (\*\*, P \< 0.001; *n* = 3). (E) Osteoclast precursor cells from control (*Bcl6^+/−^*) or *Bcl6^−/−^* mice were cultured in the presence or absence of RANKL for 5 d and subjected to May-Grünwald Giemsa and TRAP staining, and the number of multinuclear TRAP-positive cells containing more than three nuclei was determined. Data are means ± SD of cells containing more than three nuclei (\*\*, P \< 0.001; *n* = 3). (F) Bone resorbing activity in *Bcl6^+/−^* (top) and *Bcl6^−/−^* (bottom) osteoclasts was analyzed by a pit formation assay. Representatives of at least three (E) and two (F) independent experiments are shown. Bars: (A) 1 mm; (C, E, and F) 100 µm.](JEM_20091957_RGB_Fig2){#fig2}

Blimp1 regulates Bcl6 expression and osteoclastogenesis
-------------------------------------------------------

Next, we searched for a factor that might suppress Bcl6 during osteoclastogenesis and found that the transcriptional repressor *Blimp1*, also called *Prdm1*, was specifically up-regulated during osteoclast formation ([Fig. S4 A](http://www.jem.org/cgi/content/full/jem.20091957/DC1)). Blimp1 expression in osteoclasts was also demonstrated by using Blimp1-EGFP BAC transgenic mice, in which the EGFP sequence is knocked into the *Blimp1* locus, and by the observation that TRAP-positive cells showed Blimp1 expression (Fig. S4 B). RT-PCR analysis confirmed *Blimp1* induction in BMMs in the presence of RANKL in parallel with induction of *Ctsk*, a marker of osteoclast differentiation ([Fig. 3 A](#fig3){ref-type="fig"}). To determine whether Bcl6 is a Blimp1 target, an electrophoretic mobility shift assay (EMSA) was undertaken using a Bcl6 probe corresponding to a *Bcl6* regulatory region ([@bib4]). Blimp1 formed a complex with the probe, but not with a Bcl6mut probe in which two nucleotides are changed to disrupt the Blimp1 binding sequence ([Fig. S5 A](http://www.jem.org/cgi/content/full/jem.20091957/DC1)). The PRDI probe, which corresponds to a region of the *interferon β* promoter known to bind Blimp1 protein ([@bib14]) weakly but competitively, inhibited complex formation of the Bcl6 probe with Blimp1 (Fig. S5 A). In addition, unlabeled Bcl6 probe competed with labeled Bcl6 probe--Blimp1 to block complex formation, whereas unlabeled Bcl6mut probe did not (Fig. S5 A), confirming specificity and suggesting that Bcl6 is a direct Blimp1 target. Furthermore, ChIP analysis showed that, in the absence of RANKL, Blimp1 was absent from the *Bcl6* promoter, but was recruited there by RANKL treatment (Fig. S5 B). Thus, we conclude that Bcl6 is a direct target of Blimp1 in osteoclasts.

![**Blimp1 is essential for osteoclastogenesis and regulates bone homeostasis.** (A) Total RNA isolated from BMMs cultured with M-CSF and RANKL for indicated periods was subjected to RT-PCR analysis with primers specific for *Blimp1* (top), *Ctsk* (middle), and *β-actin* (bottom). Representatives of at least three independent experiments are shown. (B--F) Bone phenotypes of osteoclast-specific Blimp1 KO (Blimp1 cKO) female mice at 8 wk old. (B) Longitudinal sections of tibias of control mice (Ctl; left) and Blimp1 cKO mice (right) were stained by toluidine blue. (C) Bone parameters are shown. Data are mean bone volume per total volume (BV/TV; %), trabecular number (Tb. N; /mm), osteoblast surface per bone surface (Ob.S/BS; %), or bone formation rate per bone surface (BFR/BS; mm^3^/cm^2^/y) ± SD of control (Ctl; white bar) and Blimp1 cKO (cKO; shaded bar) mice (\*, P \< 0.01; *n* = 5). (D) Microfocus CT analysis of femurs of control mice (Ctl; left) and Blimp1 cKO mice (right). (E) TRAP staining of tibial sections of control mice (Ctl; left) and Blimp1 cKO mice (right). Osteoclast parameters are shown as mean osteoclast number per bone perimeter (N.Oc/B.Pm) or osteoclast surface per bone surface (Oc.S/BS.) ± SD of control (Ctl; white bar) and Blimp1 cKO (cKO; shaded bar) mice (*n* = 5). (F) Serum CTx levels as a marker of bone resorption of control (Ctl; white bar) and Blimp1 cKO (cKO; shaded bar) mice (\*, P \< 0.01; *n* = 5). Bars: (B and E) 100 µm; (D) 1 mm.](JEM_20091957_RGB_Fig3){#fig3}

To investigate physiological roles of Blimp1 in osteoclast differentiation, we established osteoclast-specific Blimp1 cKO mice (*Ctsk^Cre/+^Blimp1^flox/-^*), as Blimp1-null mice are embryonic lethal ([@bib41]). Blimp1 heterozygotes (*Blimp1^+/−^*) were crossed with Ctsk-Cre mice (*Ctsk^Cre/+^*) in which *Cre* is knocked into the *Ctsk* locus ([@bib26]). Next, *Ctsk^Cre/+^Blimp1^+/−^* mice were crossed with a transgenic strain harboring *loxP*-flanked (floxed) *Blimp1* alleles (*Blimp1^flox/flox^*; [@bib30]) to yield Blimp1 cKO mice. *Ctsk^Cre/+^Blimp1^flox/+^* mice served as controls. Blimp1 cKO mice showed increased trabecular bone mass and an expanded growth plate compared with control mice, as seen by histomorphometric and microradiographical analysis ([Fig. 3, B--D](#fig3){ref-type="fig"}). TRAP staining of bone sections and analysis of serum CTx levels demonstrated severe inhibition of TRAP-positive osteoclast formation and bone resorbing activity, respectively ([Fig. 3, E and F](#fig3){ref-type="fig"}). Bone-morphometric analysis revealed reduced osteoblastic parameters in Blimp1 cKO mice ([Fig. 3 C](#fig3){ref-type="fig"}). Differentiation of osteoblasts isolated from osteoclast-specific Blimp1 cKO mice did not differ from that seen in control mice ([Fig. S6](http://www.jem.org/cgi/content/full/jem.20091957/DC1)), suggesting that Blimp1 deficiency in osteoclast progenitor cells promotes decreased osteoblast differentiation and bone formation. Deletion of Blimp1 in osteoclasts did not alter precursor cell proliferation or induction of apoptosis ([Fig. S7, A and B](http://www.jem.org/cgi/content/full/jem.20091957/DC1)). Furthermore, immune cell populations such as CD3-, B220-, Mac1-, or Gr1-positive cells were normal in the Blimp1 osteoclast-specific KO, suggesting that Blimp1 is required to regulate osteoclast differentiation and bone homeostasis ([Fig. S8](http://www.jem.org/cgi/content/full/jem.20091957/DC1)).

Severe inhibition of osteoclastogenesis was also observed in in vitro culture. Multinuclear TRAP-positive osteoclast formation induced by RANKL was significantly inhibited in Blimp1 cKO cells ([Fig. 4, A and B](#fig4){ref-type="fig"}). *Blimp1* expression was significantly up-regulated in the presence of RANKL in control cells; however, *Blimp1* induction was significantly inhibited in Blimp1 cKO cells ([Fig. 4 C](#fig4){ref-type="fig"}). In contrast, *Bcl6* expression was significantly down-regulated in control cells in the presence of RANKL; however, *Bcl6* expression in Blimp1 cKO cells was significantly up-regulated in Blimp1 cKO cells, even in the presence of RANKL ([Fig. 4, C and D](#fig4){ref-type="fig"}), suggesting that Blimp1 is critical to suppress *Bcl6* expression in osteoclasts during differentiation by RANKL and is essential for regulating osteoclastogenesis.

![**Impaired osteoclastogenesis and Bcl6 expression resulting from Blimp1 deficiency.** (A--C) BMMs from control (Ctl) or Blimp1 cKO (cKO) mice were cultured in the presence or absence of RANKL for 8 d. Cells were then subjected to May-Grünwald Giemsa and TRAP staining (A), the number of TRAP-positive cells containing more than three nuclei was scored (B, left), and the number of nuclei in each multinuclear osteoclast was determined (B, right). Bar, 100 µm. Numbers are means ± SD of multinuclear cells (\*\*, P \< 0.001; *n* = 3). (C) Total RNA was prepared from control (white bars) or Blimp1 cKO (shaded bars) cells treated with (+) or without (−) RANKL, and *Blimp1* (left) or *Bcl6* (right) expression relative to *β-actin* was analyzed by quantitative real-time PCR. Data represent means ± SD of *Blimp1*/*β-actin* or *Bcl6*/*β-actin* levels (\*\*, P \< 0.001; *n* = 4). (D) Whole-cell lysates from control or Blimp1 cKO cells cultured with M-CSF alone or M-CSF plus RANKL were analyzed by immunoblotting to detect Blimp1, Bcl6, and NFATc1. Actin was analyzed as an internal control. Representatives of at least four independent experiments are shown.](JEM_20091957_RGB_Fig4){#fig4}

Bcl6 suppresses NFATc1 target genes during osteoclastogenesis
-------------------------------------------------------------

Expression of genes encoding osteoclastic factors, such as *NFATc1*, *DC-STAMP*, and *Ctsk*, all of which are targets of NFATc1 ([@bib24]; [@bib2]; [@bib43]), was markedly inhibited in Blimp1 cKO osteoclasts ([Fig. 5 A](#fig5){ref-type="fig"}). It was shown by ChIP analysis that NFATc1 was not evident on osteoclastic gene promoters without RANKL, but was recruited there after RANKL treatment of control cells ([Fig. 5 B](#fig5){ref-type="fig"}). In contrast, in the absence of RANKL, Bcl6 was present on osteoclastic gene promoters, but was lost from those promoters after RANKL treatment of control cells ([Fig. 5 B](#fig5){ref-type="fig"}). These data strongly indicate that NFATc1 and Bcl6 are reciprocally recruited to osteoclastic gene promoters. Significantly, reciprocal recruitment of NFATc1 and Bcl6 was severely impaired in Blimp1 cKO cells ([Fig. 5 B](#fig5){ref-type="fig"}), suggesting that Blimp1 up-regulation is critical for loss of Bcl6 from osteoclastic promoters after RANKL stimulation. Bcl6 was not present on the *NFATc2* promoter, which is not activated by RANKL stimulation ([@bib2]), in the presence or absence of RANKL ([Fig. 5 B](#fig5){ref-type="fig"}), suggesting that Bcl6 is selectively recruited to promoters of osteoclastic genes and inhibits osteoclast differentiation. Whereas Bcl6 was down-regulated by RANKL treatment in control cells, Bcl6 expression was maintained in Blimp1 cKO cells, even in the presence of RANKL ([Fig. 4 C](#fig4){ref-type="fig"} and [Fig. S9](http://www.jem.org/cgi/content/full/jem.20091957/DC1)). These data indicate that impaired Bcl6 down-regulation caused by loss of Blimp1 results in continuous inhibition of osteoclastic gene expression, which in turn promotes severe inhibition of osteoclastogenesis and increased bone mass.

![**Bcl6 suppresses osteoclast differentiation.** (A) Total RNA was prepared from control (white bars) or Blimp1 cKO (shaded bars) cells treated with (+) or without (−) RANKL, and the expression of the osteoclastic genes *NFATc1*, *DC-STAMP*, and *Ctsk* relative to *β-actin* was analyzed by a quantitative real-time PCR. Data are means ± SD of *osteoclastic genes*/*β-actin*. (\*\*, P \< 0.001; *n* = 4). (B) Recruitment of NFATc1 and Bcl6 to promoters of osteoclastic genes such as *NFATc1*, *DC-STAMP*, *Ctsk*, or a negative control gene *NFATc2* was analyzed by a ChIP assay. Representatives of at least four (A) or two (B) independent experiments are shown.](JEM_20091957_GS_Fig5){#fig5}

Finally, to confirm the role of Blimp1 in regulating osteoclastogenesis through Bcl6, osteoclast-specific Blimp1/Bcl6 double KO mice (double KO \[DKO\]; *Ctsk^Cre/+^Blimp1^flox/-^Bcl6^−/−^* mice) were established ([Fig. 6](#fig6){ref-type="fig"}). DKO mice exhibited decreased bone mass in vivo compared with Blimp1 cKO mice ([Fig. 6 A](#fig6){ref-type="fig"}). Similarly, progenitor cells isolated from DKO mice showed accelerated osteoclastogenesis compared with those from Blimp1 cKO mice ([Fig. 6, B and C](#fig6){ref-type="fig"}), suggesting that Blimp1 regulates osteoclastogenesis in part through controlling Bcl6. These results reveal that the Blimp1--Bcl6--osteoclastic molecule axis is critical for controlling osteoclast differentiation and bone homeostasis ([Fig. 7](#fig7){ref-type="fig"}).

![**Bcl6 is a target of Blimp1 during osteoclastogenesis.** (A) Bone mineral density (BMD) of equal longitudinal division of femurs of control (filled circles), Blimp1 cKO (open circles), and Blimp1 cKO/Bcl6 KO (DKO; filled triangles) mice. Data represent mean BMD (*n* = 4). (B and C) Osteoclast progenitor cells from control, Blimp1 cKO or DKO mice were cultured in the presence of M-CSF alone or M-CSF plus RANKL for 8 d. Cells were then subjected to May-Grünwald Giemsa and TRAP staining (B), and the number of TRAP-positive cells containing more than three nuclei was scored (C). Results are representative of three independent experiments. Bar, 100 µm.](JEM_20091957_RGB_Fig6){#fig6}

![**A schematic model of osteoclastogenesis regulated by the Blimp1-Bcl6-osteoclastic gene axis.** RANKL--RANK interaction results in Blimp1 induction, leading to Bcl6 down-regulation and dissociation of Bcl6 from osteoclastic gene promoters, an event critical for osteoclastogenesis. NFATc1 activation is induced by various factors, such as ITAM, TRAF6, c-Fos, and Ca^2+^ signaling, which are also activated by RANKL.](JEM_20091957_RGB_Fig7){#fig7}

DISCUSSION
==========

Here, we show that two transcriptional repressors, Bcl6 and Blimp1, are essential to control physiological osteoclast development and maintenance of bone homeostasis. Bcl6, a member of the POZ/BTB-zinc finger protein family, suppresses expression of "osteoclastic" genes, all of which are targets of NFATc1 ([@bib24]; [@bib2]; [@bib43]), thereby antagonizing NFATc1 function. Indeed, NFATc1 deficiency in osteoclasts results in impaired differentiation ([@bib2]), whereas Bcl6-deficient mice exhibit accelerated osteoclast formation and decreased bone mass. Blimp1, encoded by *Prdm1*, acts as a suppressor of Bcl6, likely by direct binding to the *Bcl6* promoter. In contrast to Bcl6-deficient mice, osteoclast-specific Blimp1 cKO mice display impaired osteoclast differentiation and increased bone mass. Expression of *Bcl6* and *Blimp1* is reciprocal in normal osteoclast formation, and unusual elevation of *Bcl6* expression caused by Blimp1 deficiency leads to osteoclastogenesis failure, as indicated by increased bone mass seen in a Blimp1 cKO model. Signals positively regulating NFATc1 in osteoclasts, such as TRAF6, c-Fos, ITAM-PLCγ-Ca^2+^ signals, Btk, and Tec ([@bib39]; [@bib16]; [@bib38]), have been characterized, and NFATc1 reportedly positively autoregulates in osteoclasts ([@bib2]). However, factors modulating this activity have not been described. Our study characterizes such an axis of factors that serve as a molecular switch to control osteoclastogenesis and bone homeostasis after RANKL stimulation.

To date, the skeletal and immune systems have been shown to share common molecules to achieve homeostasis ([@bib27]). RANKL and RANK were originally identified in T cells and DCs ([@bib1]), respectively, and both are essential for osteoclastogenesis ([@bib18]; [@bib6]). NFATc1 was identified in T cells and plays an essential role in osteoclast formation ([@bib29]; [@bib2]). DC-STAMP plays a role in DC function and is required for cell--cell fusion of osteoclasts and macrophage giant cells ([@bib42], [@bib43]; [@bib35]). Besides roles in immune system, Bcl6 has antiapoptotic and protooncogenic function ([@bib3]; [@bib32]). Blimp1 also functions in specification of the germ cell lineage and acts as a tumor suppressor ([@bib30]; [@bib11]). Here, we show that Bcl6 and Blimp1, which are both implicated in B cell and T cell development ([@bib40]; [@bib7]; [@bib5]; [@bib20]; [@bib8]; [@bib12]; [@bib23]; [@bib4]), have a novel function in regulating osteoclastogenesis and maintenance of bone homeostasis. It has been reported that Blimp1 represses Bcl6 ([@bib4]) or that Blimp1 and Bcl6 regulate each other ([@bib37]). Blimp1 expression was reportedly inhibited by Bcl6 ([@bib23]); however, we did not detect dysregulation of Blimp1 expression in Bcl6-deficient osteoclasts (unpublished data). Osteoclast-specific Blimp1/Bcl6 DKO mice exhibited increased osteoclastogenesis with decreased bone mass compared with Blimp1 cKO mice, indicating that Blimp1 regulates Bcl6 in osteoclasts. However, although Bcl6-deficient cells showed accelerated osteoclastogenesis compared with control cells, DKO cells showed decreased osteoclast differentiation compared with control cells, suggesting that Blimp1 regulates osteoclastogenesis through Bcl6 along with other target molecules. Blimp1 has multiple targets in lymphocytes and PGCs ([@bib36]; [@bib19]), and thus it is possible that Blimp1 has multiple targets in osteoclasts as well. In osteoclasts, several negative regulators for osteoclastogenesis, such as *Id*, *Mafb*, and *Irf*8, have been identified ([@bib21]; [@bib15]; [@bib44]). Blimp1 may also target these molecules in osteoclasts to stimulate osteoclast differentiation. Further investigations are needed to clarify the molecular mechanisms of the regulation of osteoclastogenesis by Blimp1.

We used *Ctsk^Cre/+^* mice to establish osteoclast-specific Blimp1 cKO mice because *Ctsk^Cre/+^* mice have been used to generate osteoclast-specific KOs of factors such as the estrogen receptor and Bcl-XL ([@bib26]; [@bib10]). Osteoclastogenesis, including *Ctsk* expression, has been evaluated in osteoclast-specific gene-targeted cells ([@bib26]). *Blimp1* expression is induced earlier than *Ctsk* ([Fig. 3 A](#fig3){ref-type="fig"}), and osteoclastogenesis is inhibited in Blimp1 cKO cells, suggesting that continuous Blimp1 expression is required for full osteoclast differentiation under control of RANKL. Blimp1 is also known to be induced by BMP4 and LIF in PGCs, where it functions as a transcriptional repressor ([@bib31]). In osteoclasts, Blimp1 is induced by RANKL and acts to repress Bcl6. Thus, signaling regulating Blimp1 expression differs between PGCs and osteoclasts.

Bone homeostasis requires a delicate balance between osteoclastic and osteoblastic activities. A decline in bone volume is closely related to up-regulation of osteoclast activity, and thus osteoclasts could be targeted therapeutically to treat skeletal disorders such as osteoporosis and destructive bone metastasis. FK506, a specific inhibitor of calcineurin-NFATs, inhibits osteoclastogenesis, but does not increase bone mass, as FK506 also inhibits bone formation ([@bib17]). Thus, additional factors that could negatively regulate osteoclast differentiation, such as those identified here, have been sought. Thus, our study provides new insight into regulation of osteoclastogenesis and bone homeostasis and forms the basis for developing novel therapeutic approaches to treat skeletal disorders.

MATERIALS AND METHODS
=====================

### Mice.

*Bcl6^−/−^* mice on a mixed C57BL/6 X 129/Sv background were generated by crossing *Bcl6* heterozygotes (*Bcl6^+/−^*; [@bib7]). Osteoclast-specific Blimp1 cKO mice on a C57BL/6 background were generated from three lines: mice carrying *loxP*-flanked *Blimp1* alleles (*Blimp1^flox/flox^*; [@bib30]), mice harboring *Cre* in the *Ctsk* (*Ctsk^Cre/−^*) locus ([@bib26]), and *Blimp1* heterozygotes (*Blimp1^+/−^*; provided by A. Tarakhovsky, The Rockefeller University, New York, NY). Animals were maintained under specific pathogen--free conditions in animal facilities certified by the Keio University School of Medicine animal care committee. Animal protocols were approved by the Keio University School of Medicine animal care committee.

### In vitro osteoclast formation.

BM cells isolated from long bones (femurs, tibias, and humerus) were cultured 72 h in αMEM (Sigma-Aldrich) containing 10% heat-inactivated FBS (JRH Biosciences) and GlutaMax supplemented with M-CSF (50 ng/ml; Kyowa Hakko Kirin Co.). Adherent cells were then collected for analysis. 10^5^ cells were cultured with M-CSF and recombinant soluble RANKL (25 ng/ml; PeproTech Ltd.) for indicated time periods. Mouse spleen cells were cultured overnight in αMEM containing 10% heat-inactivated FBS and GlutaMax supplemented with M-CSF. After this incubation, nonadherent cells were collected and 10^5^ cells were cultured with M-CSF and recombinant soluble RANKL (5 or 25 ng/ml) for the indicated time periods. Osteoclastogenesis was evaluated by TRAP and May-Grünwald Giemsa staining ([@bib25]; [@bib42]). RAW264.7 cells were maintained in αMEM containing 10% heat-inactivated FBS and GlutaMax and stimulated by recombinant soluble RANKL to induce osteoclast formation.

### Pit formation assay.

Bone resorbing activity of osteoclasts was analyzed as previously described ([@bib9]). In brief, osteoclast precursors isolated from indicated mice were seeded on dentin slices and cultured in the presence of M-CSF plus RANKL for 6 d. Dentin slices were then stained by toluidine blue and observed under a microscope (model BZ-9000; Keyence Co.).

### Analysis of skeletal morphology.

Bcl6^−/−^, DKO, and control littermates were necropsied 16 d after birth. Hindlimbs were removed, fixed with 70% ethanol, and subjected to dual-energy x-ray absorptiometry analysis to measure bone mineral density and for bone-histomorphometric analysis. Female 8-wk-old Blimp1 cKO mice and control littermates were administered intraperitoneal injections of 16 mg/kg calcein (Dojindo Co.) at 6 and 1 d before sacrifice to evaluate bone formation rate. Hindlimbs were removed and analyzed as described above.

### ELISA.

Serum levels of osteocalcin and C-terminal telopeptides of type I collagen (CTx) were measured by the Mouse Osteocalcin EIA kit (Biomedical Technologies Inc.) and RatLaps EIA (Immunodiagnostics Systems Ltd.), respectively. Assays were undertaken following the manufacturers' instructions.

### Real-time PCR analysis.

Total RNAs were isolated from BM cultures by TRIzol reagent (Invitrogen). After denaturation of total RNAs at 70°C for 5 min, cDNAs were synthesized from total RNAs using oligo(dT) primer and reverse transcription (Wako Pure Chemicals Industries). Real-time PCR was performed using SYBR Premix ExTaq II (Takara Bio Inc.) with the DICE Thermal cycler (Takara Bio Inc.), according to the manufacturer's instructions. Samples were matched to a standard curve generated by amplifying serially diluted products using the same PCR reactions. *β-actin* expression served as an internal control. Primer sequences were as follows: *β-actin* forward: 5′-TGAGAGGGAAATCGTGCGTGAC-3′; *β-actin* reverse: 5′-AAGAAGGAAGGCTGGAAAAGAG-3′; *Bcl6* forward: 5′-AGACGCACAGTGACAAACCATACAA-3′; *Bcl6* reverse: 5′-GCTCCACAAATGTTACAGCGATAGG-3′; *Blimp1* forward: 5′-TTCTTGTGTGGTATTGTCGGGACTT-3′; *Blimp1* reverse: 5′-TTGGGGACACTCTTTGGGTAGAGTT-3′; *Ctsk* forward: 5′-ACGGAGGCATTGACTCTGAAGATG-3′; *Ctsk* reverse: 5′-GGAAGCACCAACGAGAGGAGAAAT-3′; *DC-STAMP* forward: 5′-TCCTCCATGAACAAACAGTTCCAA-3′; *DC-STAMP* reverse: 5′-AGACGTGGTTTAGGAATGCAGCTC-3′; *NFATc1* forward: 5′-CAAGTCTCACCACAGGGCTCACTA-3′; *NFATc1* reverse: 5′-GCGTGAGAGGTTCATTCTCCAAGT-3′; *type I collagen* forward: 5′-CCTGGTAAAGATGGTGCC-3′; *type I collagen* reverse: 5′-CACCAGGTTCACCTTTCGCACC-3′; *osteocalcin* forward: 5′-TAGCAGACACCATGAGGACCCT-3′; *osteocalcin* reverse: 5′-TGGACATGAAGGCTTTGTCAGA-3′.

### Immunofluoresence.

Cells were fixed with 4% paraformaldehyde (Wako Pure Chemical Industries) in PBS solution for 15 min at room temperature. After washing to remove fixation solution, cells were permeabilized in PBS containing 0.1% Triton X-100 for 10 min at room temperature and then washed. Nonspecific antibody binding was blocked by treatment with 5% BSA (Sigma-Aldrich Co.) in PBS. Cells were then stained with anti-Bcl6 antibody (1:50 dilution, N-3; Santa Cruz Biotechnology, Inc.) at 4°C overnight, washed with PBS and stained with Alexa Fluor 546--conjugated anti-rabbit IgG antibody (1:200 dilution) for 1 h at room temperature. Cells were washed to remove secondary antibody and incubated with DAPI solution (Dojindo Co.; 1:5,000) for nuclear staining, followed by microscopic observation (model BZ-9000; Keyence Co).

### Immunoblotting analysis.

Whole-cell lysates were prepared from BM cultures using RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 5 mM EDTA, and a protease inhibitor cocktail; Sigma-Aldrich). Equivalent amounts of protein were separated by SDS-PAGE and transferred to a PVDF membrane (Millipore). Proteins were detected using the following antibodies: anti-NFATc1 (7A6), anti-Blimp1 (6D3), anti-Bcl6 (N-3) (Santa Cruz Biotechnology, Inc.), and anti-actin (A2066; Sigma-Aldrich).

### EMSA.

Nuclear extracts were prepared from COS7 cells transfected with pCAG-HA-Blimp1 or pCAG. Each extract was incubated for 30 min on ice with a \[^32^P\]labeled probe in binding buffer (10 mM Tris-HCl, pH 7.9, 50 mM NaCl, 0.5 mM EDTA, 1 mM DTT, and 10% glycerol) containing 2 µg of poly(dI-dC), KCl, and BSA. Complexes were separated on 5% polyacrylamide gels in TGE buffer (25 mM Tris-HCl, 190 mM glycine, and 1 mM EDTA). The Bcl6 probe corresponding to a putative Blimp1 binding site in the *Bcl6* gene was 5′-AGGTTTCATA­GGAAGTGAAAA­CCCTGCTAT-3′. A mutated probe (underlined residues) served as a negative control (Bcl6mut probe; 5′-AGGTTTCATA­GGAAGTTAGAA­CCCTGCTAT-3′). After electrophoresis, gels were dried and exposed to the imaging plate, and signals were analyzed using ImageGauge software on the BAS2000 image analyzer (Fuji Film Co.).

### ChIP.

ChIP was performed on osteoclasts. M-CSF--induced BMMs were cultured on 100-mm type I collagen-coated culture dishes (Asahi Glass Co.) with M-CSF and recombinant RANKL for the indicated time periods, and then subjected to ChIP analysis using the ChIP-IT Enzymatic kit (ActivMotif Inc.), according to the manufacturer's instructions. Immunoprecipitation was performed using anti-NFATc1 (7A6), anti-Bcl6 (N-3), and anti-Blimp1 (C14A4; Cell Signaling Technology). DNA was purified by QIAquick PCR purification kit (QIAGEN) and analyzed using primers corresponding to the following promoters: *NFATc1*-P1 promoter, 5′-CCGGGACGCC­CATGCAATCTG­TTAGTAATT-3′ (sense) and 5′-GCGGGTGCCC­TGAGAAAGCTA­CTCTCCCTT-3′ (antisense); the *DC-STAMP* promoter, 5′-GGGGGTCCTCATTTCTACAACTCAT-3′ (sense) and 5′-GCCACATCACCCTGAATCAATCTT-3′ (antisense); the *Ctsk* promoter, 5′-CCTTAAACTGGCTCCTGTCAAAGA-3′ (sense) and 5′-CCCTTCTTCAGAAGCCCTGTAAT-3′ (antisense); *NFATc2* promoter, 5′-TTATCAGGGA­GCACTGCCCAT­CTCCGCTTT-3′ (sense) and 5′-CGGTCTGGCC­TGAGCGACAGG­CCCAGACAA-3′ (antisense); and *Bcl6* promoter, 5′-CAGCCACCCTGAGTTTACAA-3′ (sense) and 5′-CGTTCCAGCACTGTTTTGAA-3′ (antisense).

### Microarray analysis.

BM cells were isolated from 8-wk-old mouse and cultured in the presence of M-CSF for 3 d. M-CSF--dependent adherent cells were harvested and cultured with M-CSF alone for macrophages and M-CSF plus RANKL for osteoclasts, respectively. After 6 days of cultivation, total RNA was isolated and microarray analysis was undertaken using GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Data were analyzed using GeneChip Operating Software and deposited in Minimum Information about a Microarray Experiment compliant in Gene Expression Omnibus (GEO accession no. [GSE20850](GSE20850)).

### Online supplemental material.

Fig. S1 shows that *Bcl6* is transcriptionally repressed by RANKL. Fig. S2 shows bone parameters of *Bcl6^+/−^* and *Bcl6^−/−^* mice. Fig. S3 shows proliferation and apoptosis of osteoclast precursors from *Bcl6^+/−^* and *Bcl6^−/−^* mice. Fig. S4 shows Blimp1 expression in osteoclasts. Fig. S5 shows that Blimp1 binds to the Bcl6 promoter. Fig. S6 shows normal osteoblastic differentiation in Blimp1 cKO cells. Fig. S7 shows proliferation and apoptosis of osteoclast precursors from Blimp1 cKO and control mice. Fig. S8 shows immune cell populations in spleens of Blimp1 cKO and control mice. Fig. S9 shows dysregulation of Bcl6 in Blimp1 cKO BMM. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20091957/DC1>.
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